Home General Biotechnology Drug Patent Expirations in June 2012

Drug Patent Expirations in June 2012

Drug Patent Expirations in June 2012

*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent NumberPatent Expiration
IONSYSIncline Therapfentanyl hydrochloride6,317,629Jun 2, 2012
SULARShionogi Incnisoldipine5,422,123Jun 6, 2012
REQUIP XLSmithkline Beechamropinirole hydrochloride5,422,123Jun 6, 2012
ZYFLO CRCornerstone Therapzileuton5,422,123Jun 6, 2012
DILACOR XRWatson Labsdiltiazem hydrochloride5,422,123Jun 6, 2012
VIGAMOXAlcon Pharms Ltdmoxifloxacin hydrochloride4,990,517*PEDJun 8, 2012
MOXEZAAlcon Pharms Ltdmoxifloxacin hydrochloride4,990,517*PEDJun 8, 2012
IMITREXGlaxosmithklinesumatriptan5,705,520*PEDJun 10, 2012
LESCOLNovartisfluvastatin sodium5,356,896*PEDJun 12, 2012
LESCOL XLNovartisfluvastatin sodium5,356,896*PEDJun 12, 2012
TRIZIVIRViiv Hlthcareabacavir sulfate; lamivudine; zidovudine5,034,394*PEDJun 18, 2012
EPZICOMViiv Hlthcareabacavir sulfate; lamivudine5,034,394*PEDJun 18, 2012
ZIAGENViiv Hlthcareabacavir sulfate5,034,394*PEDJun 18, 2012
CHILDREN’S MOTRINMcneil Consibuprofen5,374,659*PEDJun 20, 2012
MOTRINMcneil Consumeribuprofen5,374,659*PEDJun 20, 2012
CHILDREN’S MOTRINMcneilibuprofen5,374,659*PEDJun 20, 2012
EDARBYCLORTakeda Pharmsazilsartan kamedoxomil; chlorthalidone5,736,555Jun 25, 2012
NEORALNovartiscyclosporine6,258,808Jun 25, 2012
EDARBITakeda Pharmsazilsartan kamedoxomil5,736,555Jun 25, 2012
NEORALNovartiscyclosporine6,262,022Jun 25, 2012

 

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com

NO COMMENTS

  1. In renewing the patents, is it the financial value of patenting process of each particular drugs varies or said to be much more higher from each another based on their sales data? like what if they are top selling drugs in the market that probably make more money when compare with others? and how about those drugs with multiple patents?

  2. well, now some kind of generics/or copied products now have the ability to be manufactured and produced by other company based on the procedure and information regarding the drugs. hence, products can go on sell and have a market to capture.

Leave a Reply